Ananda Pharma PLC - Interims for the six months ended 31 July 2025

13 October 2025

ANANDA PHARMA PLC 

("Ananda" or the "Company") 

Unaudited Interim Results for the six months ended 31 July 2025

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that unaudited, consolidated interim accounts for the period ending 31 July 2025.

The Directors present the consolidated interim results of Ananda Pharma Plc ("the Company"), together with its subsidiaries ("the Group") for the period from 1 February 2025 to 31 July 2025.

UPDATE ON OPERATIONS

Corporate

In February, we appointed Viridian Capital as advisors to the Company. Viridian is a US based investment bank with a long and successful history of mergers, acquisitions and capital raising in the North American cannabis sector. We have identified the US as the main target market both from a funding and a commercial perspective, given its depth in pharmaceuticals and cannabis businesses. Since appointing Viridian we have been working with their president and founder, Scott Greiper, on refining the Ananda story and how we communicate that story to make sure we are properly prepared for the US market activities. To support this US focus and increase corporate visibility, we have had Ananda's shares admitted to trading on the OTC exchange in New York under ticker ANANF.

During the period Chris Tovey, Giles Moss and Andy Rust were also appointed as Advisors. Chris and Giles are both ex-GW Pharma senior executives. Chris, in particular,  was part of the GW team which took Epidiolex through Federal Drug Administration ('FDA') and EMA regulatory approvals, was a key driver of GW Pharma's ('GW') IPO onto NASDAQ and its sale to Jazz Pharmaceuticals for USD7.2bn in 2021. Giles was a senior European executive with the group.  Together they bring significant expertise in CBD drug development and regulatory approvals as well as experience working for a quoted pharmaceutical company and managing very large and complex transactions. We see them as key resources as MRX1 moves through its clinical development and also as we grow Ananda corporately.

Andy is a veteran of pharmaceutical sales, with specific experience in pain medication sales in the US. His most recent role was as Head of Respiratory at Chiesi Group, where he led the strategic direction of the group's portfolio, helping grow revenues of the respiratory range to over €1.5 billion. Andy is on board to provide long-range strategic thinking for Ananda as we begin to plan in detail our go to market strategy.

MRX1 (Phase 1 Pharmacokinetic study ('PK'), Chemotherapy Induced Peripheral Neuropathy ('CIPN') & Endometriosis)

We have now completed the development work for MRX1. We have gathered the required stability data (2 years), produced the required number of consistent 'trial' manufacturing batches (3) and completed the Dossier that sits alongside MRX1 as an 'Investigational Medicine' ('IM'). This work is required for all IMs ahead of use in a clinical trial/setting. Following completion of this work, we completed the manufacturing of a GMP (Good Manufacturing Practices) batch of MRX1 for use in all three of our MRX1 clinical trials. 40 litres were formulated, representing the first half of the required volume for the CIPN and endometriosis trials and all of the required volume of MRX1 for our Phase 1 study in Australia.

Regarding the Phase 1 study, we delivered the required volume of MRX1 CBD formulation to the trial site in Melbourne, Australia. The Phase 1 trial is designed to give us detailed data on the pharmacokinetic profile of MRX1including safety, tolerability, food effect and PK of MRX1. PK is the way the body absorbs a drug, how it stays in the body and the rate of excretion. Following the end of the period, we announced that the last participant had completed dosing and that next milestones on this study are 1) confirmation of no adverse events, expected before the end of the year, and 2) the final study report, due in Q1 2026.

As the Phase 1 study ran in Australia, we will be due an R&D tax rebate of up to 43.5% of qualifying expenditure, making it the most cost-effective location to run the trial without sacrificing regulatory robustness - Australian trial data is readily accepted by the FDA and MHRA. The first year's R&D tax return was recently submitted and the cash rebate will be disclosed as part of the next set of Group accounts.

On CIPN and endometriosis, we have been working with the clinical trial teams to prepare the protocols and supporting documents for trial commencement. We expect to receive ethics approvals for both trials before the end of the year and for recruitment to start shortly thereafter. The timeline of the endometriosis and CIPN trials is independent of the Phase 1 PK study read out and will run concurrently.

To conclude, I have to say that the past year has absolutely flown by, and we have done a huge amount to refine our strategy. The highlight  of the period was Ananda  transitioning to a clinical stage company which has dosed participants with MRX1 CBD. This is a huge step forward for us and has proved a great learning experience in managing clinical activity. This learning will be invaluable as we move to recruitment and dosing of the first patients in the Phase 2 and 3 trials. In Q1 2026

We do all this because 1 in 10 women suffer from endometriosis and far too many people suffer from chemotherapy induced peripheral neuropathy.  Our efforts are designed to help these patients while also delivering returns to our supportive shareholders.  It is only possible because we have small but mighty team.  Thanks to them we keep kicking the goals that will pay off.

In the period, the Group incurred a loss of £1,954,291 before tax, which solely represents operational costs. Net assets of the Group at the interim point were £295,383.

On behalf of the board

Melissa Sturgess, Chief Executive Officer

13 October 2025

The directors present their consolidated interim financial statements of the Group for the period from 1 February 2025 to 31 July 2025.

Directors of the company

The directors who have served during the period and up to the date of approval were as follows:

Charles Morgan

Melissa Sturgess

John Treacy

Stuart Piccaver

Clive Page

Jeremy Sturgess-Smith

Results

The consolidated statement of comprehensive income is set out on page 7 and shows the loss for six-month period to 31 July 2025. The directors consider the loss for the period to be in line with expectations. The directors do not recommend the payment of a dividend.

This report was approved by the Board and signed on its behalf.

Melissa Sturgess, Chief Executive Officer

13 October 2025

There was no other comprehensive income in the period.

The consolidated interim financial statements were approved and authorised for issue by the Board and were signed on its behalf by:

Melissa Sturgess

Chief Executive Officer

 [13 October 2025